NASDAQ:GRCE

Grace Therapeutics Q1 2026 Earnings Results & Report

Grace Therapeutics logo
$1.71 -0.02 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 -0.01 (-0.35%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics beat analyst earnings expectations in its Q1 2026 results, released August 12, 2025. The company reported EPS of -$0.21 versus the -$0.22 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Grace Therapeutics EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.22
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Q1 2026 Earnings FAQ

Grace Therapeutics (NASDAQ:GRCE) reported earnings of -$0.21 per share for Q1 2026, beating the consensus estimate of -$0.22. The report was announced on Tuesday, August 12, 2025.

Grace Therapeutics Earnings Headlines

6 Men Secretly Changed America’s Money. Now It’s Happening Again
In 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's financial system for generations. Now six financial giants controlling $24 trillion have aligned behind a new initiative that Grey Swan Investment Fraternity's Andrew Packer says could echo that moment in history. Addison Wiggin outlines three steps investors might consider before November 30th, including one stock ticker being shared at no cost.tc pixel
Grace: Fiscal Q2 earnings snapshot
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders.

The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments.

Grace Therapeutics was formerly known as Acasti Pharma and adopted its current name as it focused on the development programs associated with Grace Therapeutics. The company’s candidates remain investigational and are not approved medicines.

View Grace Therapeutics Profile